At Manningham Medical Centre, you can find all the data about Exenatide Medical Journal. We have collected data about general practitioners, medical and surgical specialists, dental, pharmacy and more. Please see the links below for the information you need.


Exenatide - StatPearls - NCBI Bookshelf

    https://www.ncbi.nlm.nih.gov/books/NBK518981/

    Effects of Once-Weekly Exenatide on …

      https://www.nejm.org/doi/full/10.1056/NEJMoa1612917
      A once-weekly, injectable, extended-release formulation of exenatide, an exendin-4–based GLP-1 receptor agonist …

    Exenatide: pharmacokinetics, clinical use, and future …

      https://pubmed.ncbi.nlm.nih.gov/28085521/
      The first-in-class glucagon-like peptide-1 receptor agonist (GLP-1RA) exenatide, which was initially approved in 2005, is available in twice-daily (BID) and once-weekly (QW) …

    Commentary: Exenatide QW: A New Treatment Option …

      https://diabetesjournals.org/clinical/article/30/3/92/30875/Commentary-Exenatide-QW-A-New-Treatment-Option-for
      Exenatide QW has been shown to produce lower A1C values than insulin glargine over the course of an 84-week study, with accompanying significant and durable …

    Exenatide and Rare Adverse Events | NEJM - New …

      https://www.nejm.org/doi/full/10.1056/NEJMc0707137
      Exenatide, an incretin mimetic, was approved by the Food and Drug Administration (FDA) on April 28, 2005, as adjunctive therapy to improve glycemic control …

    Short-term combined treatment with exenatide and …

      https://journals.lww.com/cmj/Fulltext/2021/12050/Short_term_combined_treatment_with_exenatide_and.17.aspx
      Exenatide once-weekly (QW) is the newest member of GLP-1 receptor agonists class. At the initial stage after subcutaneous injection, the surface-bound …

    Exenatide: a review from pharmacology to clinical practice

      https://pubmed.ncbi.nlm.nih.gov/19383034/
      Abstract. Background: Exenatide is an incretin mimetic that activates glucagon-like-peptide-1 receptors. It blunts the postprandial rise of plasma glucose by increasing glucose …

    Exenatide | American Journal of Health-System …

      https://academic.oup.com/ajhp/article-abstract/63/5/411/5134608
      Exenatide (Byetta, Amylin Pharmaceuticals, San Diego, CA) is an incretin mimetic that enhances glucose-dependent insulin secretion and has several other …

    Efficacy and tolerability of exenatide monotherapy in …

      https://journals.lww.com/cmj/Fulltext/2012/08010/Efficacy_and_tolerability_of_exenatide_monotherapy.6.aspx
      Exenatide is the first glucagon like peptide-1 (GLP-1) receptor agonist available for the treatment of type 2 diabetes and serves as a promising anti-diabetic agents, since …

    Exenatide: pharmacokinetics, clinical use, and future …

      https://www.tandfonline.com/doi/full/10.1080/14656566.2017.1282463
      In an analysis of 3763 patients receiving exenatide BID and 781 receiving exenatide QW, 36.7% of patients were anti-exenatide antibody positive after 30-weeks treatment with …



    Need more information about Exenatide Medical Journal?

    At Manningham Medical Centre, we collected data on more than just Exenatide Medical Journal. There is a lot of other useful information. Visit the related pages or our most popular pages. Also check out our Doctors page.